Jiangsu Changyou Environmental Protection Technology
301557
Hefei conver Holding
603409
LIERDA
832149
SHENGNAN TECHNOLOGY
837006
CHK
831167
CN Stock MarketDetailed Quotes
300463 Maccura Biotechnology
- 13.07
- +0.15+1.16%
Market Closed Mar 4 15:00 CST
8.00BMarket Cap24.61P/E (TTM)
13.11High12.85Low45.59KlotVolume12.92Open12.92Pre Close59.38MTurnover0.93%Turnover Ratio25.63P/E (Static)612.47MShares17.3152wk High1.22P/B6.42BFloat Cap10.8852wk Low15.50Limit Up491.50MShs Float63.84Historical High10.34Limit Down2.01%Amplitude9.10Historical Low0.15Dividend TTM13.02Avg Price20.23KlotAsk1.18%Div YieldTTM100Lot Size24.78KlotBid
Maccura Biotechnology News
Mike Biotech (300463): Net profit from the mother in the second quarter increased 40% year-on-year, and the amount of self-produced reagents was quickly released
Mike Biotech (300463): The steady growth line of pharmaceutical/autonomous products for essential consumption is progressing smoothly
Mike Biotech (300463): Brilliant assembly line installation gradually drives reagent release
Mike Biotech (300463): 24Q2 rapid profit growth pipeline drives future growth
Mike Biotech (300463): The main business is steadily improving, and the performance is impressive in shipping instruments
Mike Biotech (300463): Continuing to promote strategic transformation, intelligent inspection and analysis lines performed brilliantly
Mike Biotech (300463): Product structure optimization assembly line promotion is smooth
Guolian Securities released a research report on April 27 stating that it gave Mike Biotech (300463.SZ) a purchase rating, and the target price was 15.10 yuan. The main reasons for the rating include: 1) the installed performance of the assembly line is i
Mike Biotech (300463): Continued high R&D investment to build high-end assembly lines to enhance competitiveness
Mike Biotech (300463): Excellent assembly line performance, optimistic about subsequent reagent dosage
Mike Biotech (300463): The development trend of the company's core business has improved in 23 years
Mike Biotech (300463): Asset impairment losses drag down profit pipeline promotion smoothly
Mike Biotech (300463) 2023 semi-annual report review: The decline in COVID-19 products has put pressure on performance and steady growth in conventional products
Mike Biotech (300463): New Product Release Is Imminent, Agents Accelerate Divestment to Improve Profitability
Mike Biotech (300463): Performance in the first half of the year was under pressure, assembly lines were installed quickly
Mike Biotech (300463): Steady growth of conventional reagents continues to break through the pipeline
Mike Biotech (300463): Assembly line installation is progressing smoothly, and we are optimistic about the growth of self-produced products
Mike Biotech (300463): Short-term performance pressure-bearing assembly line achieves rapid installation
Mike Biotech (300463): The core business of 1H23 is developing steadily
Mike Biotech (300463): Steadily increasing the proportion of self-produced products to enhance assembly lines and enhance long-term competitiveness
